The Israelis invest in technology, innovation, and education. The Palestinian Authority and Hamas invest in jihad, Jew-hatred, and violence. The Left demands that you boycott the former. The greatest weapon against the neo-Nazi BDS Movement is Israeli technology and innovation.
Quick note: Tech giants are shutting us down. You know this. Twitter, LinkedIn, Google Adsense, Pinterest permanently banned us. Facebook, Google search et al have shadow-banned, suspended and deleted us from your news feeds. They are disappearing us. But we are here. We will not waver. We will not tire. We will not falter, and we will not fail. Freedom will prevail.
Subscribe to Geller Report newsletter here — it’s free and it’s critical NOW when informed decision making and opinion is essential to America's survival. Share our posts on your social channels and with your email contacts. Fight the great fight.
Remember, YOU make the work possible. If you can, please contribute to Geller Report.
Israeli Students Develop App to Help the Blind Cross the Street
By Technion, September 8th, 2019:
The app was developed by two students from the Viterbi Faculty of Electrical Engineering
Roni Ash and Dolev Ofri, students from the Viterbi Faculty of Electrical Engineering at the Technion–Israel Institute of Technology, have developed an innovative application expected to significantly assist the visually impaired and the blind. The app was presented at the 2018 ICSEE International Conference in Eilat, Israel, and won the Thomas Schwartz Outstanding Project Award.
The app allows visually impaired pedestrians to safely cross the street at a traffic light. It recognizes the pedestrian traffic light and notifies the user of its color. The user is only required to point the phone camera in the desired general direction – it does not need to be accurate – and the app notifies him or her if it is possible to cross. The need for the development of such assistive technology is particularly great when it comes to a crosswalk where there is no audio indication for the blind.
The app’s high credibility is based on deep learning, training an artificial neural network that learns to identify the traffic light color based on a large set of traffic light examples. The dataset used for training the system was built by the students who developed the app as an undergraduate final project in the Signal and Image Processing Laboratory (SIPL) of the Viterbi Faculty of Electrical Engineering, headed by Professor David Malah and Laboratory Engineer Nimrod Peleg. They performed the project under the guidance of Laboratory Engineer Yair Moshe and also received help from student Ayelet Cohen. The project is a collaboration of the lab with the social hub at the Technion.
To increase awareness of using the app and demonstrate its use, its creators are shooting these days a short humorous video. The video will be directed by filmmaker Elad Kidan, an Ophir Award winner, who heard about the app and volunteered for the task.
Roni Ash and Dolev Ofri, students from the Viterbi Faculty of Electrical Engineering at the Technion – Israel Institute of Technology, have developed an innovative application expected to significantly assist the visually impaired and the blind. The app was presented at the 2018 ICSEE International Conference in Eilat, Israel, and won the Thomas Schwartz Outstanding Project Award.Read more: https://www.technion.ac.il/en/2019/08/app-to-the-blind-cross-the-street/
Posted by Technion – Israel Institute of Technology. הטכניון on Friday, August 9, 2019
Roni Ash and Dolev Ofri, students from the Viterbi Faculty of Electrical Engineering at the Technion – Israel Institute of Technology, have developed an innovative application expected to significantly assist the visually impaired and the blind. The app was presented at the 2018 ICSEE International Conference in Eilat, Israel, and won the Thomas Schwartz Outstanding Project Award.
Related: ISRAEL’S MEDICAL BREAKTHROUGHS ARE IMPROVING THE LIVES OF MILLIONS OF PEOPLE.
ISRAELI-MADE INNOVATIVE CANCER TREATMENT GETS FDA STAMP OF APPROVAL
During pivotal trials that led to the drug’s approval, approximately 40% of patients saw their tumors shrink in size.
By Jerusalem Post, September 5, 2019:
The world’s first drug to prevent proliferation of cancerous cells, established by Israeli scientist Dr. Sharon Shacham, just received FDA approval, kicking off Leukemia Awareness Month.
XPOVIO was developed by Karyopharm Therapeutics, a Newton, Massachusetts company established by Israel’s Dr. Sharon Shacham.
“We believe that our activity at Karyopharm constitutes an important milestone in the war on cancer,” she said.
The FDA first approved the drug for sale in July after 10 years of development. Karyopharm wrote in a press release that within six days of the FDA’s approval, cancer patients in the USA began receiving XPOVIO.
During a pivotal trial that led to the drug’s approval, approximately 40% of patients saw their tumors shrink. Karyopharm also reported that patient life expectancy increased by three to five times thanks to the treatment.
XPOVIO has been mainly used to treat myeloma, the second most common type of blood cancer, which affects 400 to 500 people in Israel annually, according to a Karyopharm Therapeutics press release.
Have a tip we should know? Your anonymity is NEVER compromised. Email email@example.com
The Truth Must be Told
Your contribution supports independent journalism
Please take a moment to consider this. Now, more than ever, people are reading Geller Report for news they won't get anywhere else. But advertising revenues have all but disappeared. Google Adsense is the online advertising monopoly and they have banned us. Social media giants like Facebook and Twitter have blocked and shadow-banned our accounts. But we won't put up a paywall. Because never has the free world needed independent journalism more.
Everyone who reads our reporting knows the Geller Report covers the news the media won't. We cannot do our ground-breaking report without your support. We must continue to report on the global jihad and the left's war on freedom. Our readers’ contributions make that possible.
Geller Report's independent, investigative journalism takes a lot of time, money and hard work to produce. But we do it because we believe our work is critical in the fight for freedom and because it is your fight, too.
Please contribute here.
Make a monthly commitment to support The Geller Report – choose the option that suits you best.